Medtronic (Minneapolis) reported early last month its receipt of the CE mark for its Endeavor Drug-Eluting Coronary Stent with Rapid Exchange Delivery System and said it planned to launch the drug-eluting stent (DES) system simultaneously in 40 countries, outside the U.S.